Literature DB >> 19230154

Influenza vaccine supply: building long-term sustainability.

Norbert Hehme1, Tony Colegate, Bram Palache, Luc Hessel.   

Abstract

Influenza represents a public health paradox. The virus is responsible for significant death, disease and economic loss. However, despite the availability of safe and efficacious vaccines, uptake is poor. While policy makers increasingly recognize the value of annual immunization, and vaccine supply is increasing, further efforts are required to implement existing vaccination recommendations and drive the long-term demand that supports supply sustainability. This is equally important for pandemic vaccine supply, which will rely on the same production plants and manufacturing approaches. Technological advances and capacity expansions now offer the prospect of billions of doses of vaccine in the event of a pandemic, and the availability of pre-pandemic vaccines for stockpiling and pre-emptive use. As a result, vaccination strategies utilizing pre-pandemic vaccines, combined with vaccines matched to a pandemic strain once available, offer for the first time a viable approach for mitigating an influenza pandemic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230154     DOI: 10.1016/j.vaccine.2008.07.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Impact of precautionary behaviors during outbreaks of pandemic influenza: modeling of regional differences.

Authors:  Joakim Ekberg; Henrik Eriksson; Magnus Morin; Einar Holm; Magnus Strömgren; Toomas Timpka
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

Review 2.  The use of mathematical models to inform influenza pandemic preparedness and response.

Authors:  Joseph T Wu; Benjamin J Cowling
Journal:  Exp Biol Med (Maywood)       Date:  2011-07-04

3.  Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.

Authors:  Yeu-Chun Kim; Jae-Min Song; Aleksandr S Lipatov; Seong-O Choi; Jeong Woo Lee; Ruben O Donis; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Eur J Pharm Biopharm       Date:  2012-04-03       Impact factor: 5.571

4.  Economics of influenza vaccine administration timing for children.

Authors:  Bruce Y Lee; Julie H Y Tai; Rachel R Bailey; Kenneth J Smith; Andrew J Nowalk
Journal:  Am J Manag Care       Date:  2010-03       Impact factor: 2.229

5.  Models of RNA virus evolution and their roles in vaccine design.

Authors:  Samuel Ojosnegros; Niko Beerenwinkel
Journal:  Immunome Res       Date:  2010-11-03

6.  Construction of recombinant bacmid containing m2e-ctxb and producing the fusion protein in insect cell lines.

Authors:  Nima Mirzaei; Talat Mokhtari Azad; Rakhshandeh Nategh; Hoorieh Soleimanjahi; Nour Amirmozafari
Journal:  Iran Red Crescent Med J       Date:  2014-02-07       Impact factor: 0.611

Review 7.  Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges.

Authors:  Luc Hessel
Journal:  Influenza Other Respir Viruses       Date:  2009-07       Impact factor: 4.380

8.  Considerations for sustainable influenza vaccine production in developing countries.

Authors:  Claudia Nannei; Christopher Chadwick; Hiba Fatima; Shoshanna Goldin; Myriam Grubo; Alexandra Ganim
Journal:  Vaccine       Date:  2016-09-07       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.